The Orphan Drug Act encourages the development of products for rare diseases and conditions. Many conditions that stand to benefit from stem cell-based products are rare diseases. We address the Orphan Drug Act in relation to the development of stem cell-based products
While the safety and availability of medicinal products for the majority of adult patients has stead...
Estimates of the frequencies of rare disorders vary from country to country; the global average defi...
In this article, we examine the Orphan Drug Act with an eye toward its contribution to the public in...
The Orphan Drug Act encourages the development of products for rare diseases and conditions. Many co...
ABSTRACT Rare diseases are a major public health problem and public health challenge. Orphan drugs ...
The Orphan Drug Act (ODA) [1], first enacted in the United States in 1983, was set up to encourage t...
The World Health Organization defines orphan diseases, as all pathological conditions, affecting 0....
Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of MoldovaThe aim of t...
More than 10 years have been passed since the European Parliament approved a law to encourage pharma...
significant changes within the pharmaceutical industry regarding resources expended to develop produ...
A rare disease is a health disorder that affects a small proportion (i.e., <1:2,000 in Europe) of th...
The development of vaccines against rare emerging infectious diseases is hampered by many disincenti...
Rare diseases have a prevalence of lower than 5 in 10,000 inhabitants and are life-threatening or ch...
In the last twenty years, orphan drug legislation (ODL) has been adopted in several countries around...
The development of vaccines against rare emerging infectious diseases is hampered by many disincenti...
While the safety and availability of medicinal products for the majority of adult patients has stead...
Estimates of the frequencies of rare disorders vary from country to country; the global average defi...
In this article, we examine the Orphan Drug Act with an eye toward its contribution to the public in...
The Orphan Drug Act encourages the development of products for rare diseases and conditions. Many co...
ABSTRACT Rare diseases are a major public health problem and public health challenge. Orphan drugs ...
The Orphan Drug Act (ODA) [1], first enacted in the United States in 1983, was set up to encourage t...
The World Health Organization defines orphan diseases, as all pathological conditions, affecting 0....
Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of MoldovaThe aim of t...
More than 10 years have been passed since the European Parliament approved a law to encourage pharma...
significant changes within the pharmaceutical industry regarding resources expended to develop produ...
A rare disease is a health disorder that affects a small proportion (i.e., <1:2,000 in Europe) of th...
The development of vaccines against rare emerging infectious diseases is hampered by many disincenti...
Rare diseases have a prevalence of lower than 5 in 10,000 inhabitants and are life-threatening or ch...
In the last twenty years, orphan drug legislation (ODL) has been adopted in several countries around...
The development of vaccines against rare emerging infectious diseases is hampered by many disincenti...
While the safety and availability of medicinal products for the majority of adult patients has stead...
Estimates of the frequencies of rare disorders vary from country to country; the global average defi...
In this article, we examine the Orphan Drug Act with an eye toward its contribution to the public in...
DOI
Add to ORKG